Histoplasmosis Treatment Market Outlook:
Histoplasmosis Treatment Market size was valued at USD 1.3 billion in 2025 and is projected to reach USD 2.2 billion by the end of 2035, increasing at a CAGR of 5.2% during the forecast period, i.e., 2026-2035. In 2026, the industry size of histoplasmosis treatment is estimated at USD 1.4 billion.
The international patient pool in the market is recorded between 1 to 2 cases per 100,000 yearly population, the death cases are registered at around 5%, and higher rates are seen in the adult population, based on the CDC report in April 2024. According to the NLM report in April 2023, 90% proportion of critical disseminated histoplasmosis cases occur mainly among immunocompromised patients, which includes people with AIDS and post-transplant conditions, often representing the vast majority. Besides, the supply chain facility in the market heavily depends on active pharmaceutical ingredients (APIs), which are sourced from India, catering to international antifungal API manufacturing, thus suitable for uplifting the market globally.
Investments in research, development, and deployment of new therapeutics are mainly driven by public and non-profit organizations due to the orphan disease nature of disseminated histoplasmosis. The NIH has funded clinical research in fungal infections, while the Global Action Fund for Fungal Infections has enhanced diagnostic and treatment availability in low-resource environments. According to the NLM article in June 2025, the U.S. government continues to face substantial costs from fungal diseases estimated at more than USD 13.4 billion in direct medical expenditure and USD 6 billion in indirect expenses, suggesting an ongoing necessity for investment in prevention, diagnosis, and treatment.
